Dr. Reddy's Laboratories Ltd. can begin importing products to the United States from a Mexican chemical factory that had come under the scrutiny of U.S. regulators.
Dr. Reddy's, a generic drugmaker based in India, said last year that it had received an FDA warning letter over the location, which makes drug ingredients.
The company said the Food and Drug Administration had inspected its Cuernavaca, Mexico, plant and issued a Form 483 with observations. These forms are issued when an inspection finds deficiencies at a pharmaceutical manufacturing plant.
Dr. Reddy's did not elaborate on details of the letter but said it worked with regulators to resolve the observations in it.